Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
about
AR Signaling in Breast Cancer.Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.Nuclear receptor NR4A1 is a tumor suppressor down-regulated in triple-negative breast cancerMechanism of EGCG promoting apoptosis of MCF-7 cell line in human breast cancer.Capecitabine for primary breast cancer.
P2860
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Role of TP53 mutations in trip ...... ine/taxane-based chemotherapy.
@en
Role of TP53 mutations in trip ...... ine/taxane-based chemotherapy.
@nl
type
label
Role of TP53 mutations in trip ...... ine/taxane-based chemotherapy.
@en
Role of TP53 mutations in trip ...... ine/taxane-based chemotherapy.
@nl
prefLabel
Role of TP53 mutations in trip ...... ine/taxane-based chemotherapy.
@en
Role of TP53 mutations in trip ...... ine/taxane-based chemotherapy.
@nl
P2093
P2860
P50
P356
P1433
P1476
Role of TP53 mutations in trip ...... ine/taxane-based chemotherapy.
@en
P2093
Albrecht Stenzinger
Bruno Sinn
Christian Jackisch
Christian Schem
Christoph Salat
Gunter von Minckwitz
Hans Tesch
Jens-Uwe Blohmer
Markus Möbs
Peter Klare
P2860
P304
67686-67698
P356
10.18632/ONCOTARGET.11891
P407
P577
2016-09-07T00:00:00Z